The outcome of revision external dacryocystorhinostomy with or without mitomycin C: A single-center experience

To compare the outcome of revision external dacryocystorhinostomy (DCR) with or without mitomycin C. This Quasi prospective study was conducted over 30 diagnosed patients with failed external dacryocystorhinostomy came to the Oculoplasty clinic at Ispahani Islamia Eye Institute and Hospital from July 2019 to June 2020. Maximum of 40.0% of the patients were 41–50 age group in Group A (Mitomycin C) and 40.0% in 41-50 age group in Group B (without Mitomycin C). There were 7(46.7%) males, and 54-58 8(53.3%) females in Group A, 6(40.0%) male and 9(60.0%) female in Group B. 18(60%) patients underwent left-sided and 12(40%) patients underwent right-sided revision dacryocystorhinostomy respectively. Most patients had no complications in both groups of this study. Only one patient reported with corneal epithelial defect in the mitomycin C group. After six months follow up, 93.3% success rate was seen in revision external DCR with mitomycin C group and 66.7% in revision external DCR without mitomycin C group. Mitomycin C has a beneficial effect in preventing reclosure of the dacryocystorhinostomy stoma after revision external dacryocystorhinostomy and no significant complications resulting from its use.